The trial of the Oxford University Covid vaccine was postponed’ due to the negative reaction of the participants.

A trial participant has been denied’ the promise of the Covid-19 vaccine due to a negative reaction.

The trial of the Oxford University Covid vaccine was postponed’ due to the negative reaction of the participants.

A spokeswoman for AstraZeneca, a company that works with the Oxford University team, told the Guardian that one of the participants had been put’ on trial for "potentially unknown illness".

The spokesman stressed that adverse reactions were recorded in only one participant, and said that it was common to stop trials during vaccine’ development.

The spokesman said in a statement: "As part of the ongoing randomized, controlled global trial of the Oxford coronavirus vaccine, our standard review process was activated and we volunteered to provide safety data through an independent committee. Was prevented’ from reviewing the data. "

"This is a normal procedure that has to be done whenever there is an unknown disease in any trial, while it is being investigated. This ensures that we maintain the integrity of the trials." In large trials, the disease will be accidental, but it must be carefully examined’ independently.

We're working to speed up review of the same program to minimize any potential impact on the trial timeline. We adhere to the highest standards of safety and conduct of our partners in our trials.

The vaccine, which was expected’ to be available to the public by January 2021, is one of two projects under which the Australian government has agreed to provide free vaccines to all citizens under an agreement 1.7 It will cost billions of dollars.

On Monday, the Morrison government pledged to buy 33.8 million doses of the vaccine, if successful.

In response to the announcement, Australian Deputy Chief Medical Officer Nick Coatsworth said the trial "would not in any way keep the vaccine completely off the table."

"In a way, it reinforces that despite the rapid nature of vaccine development, safety is at the forefront of everyone's mind and if there is a strong reaction, it will be a fair standard and they will "I'm not sure if it's related to that. The vaccine, too," he told the Seven Network.

"They are gathering all the information and are currently on trial. We now have tens of thousands of people receiving this vaccine, so it is a testament to the rigor and safety that people are developing the vaccine for.

The Oxford University vaccine, which is to be given’ in multiple doses, has entered three phases of trials in the United Kingdom, the United States, Brazil, South Africa and India, and before that it could provoke strong reactions from the immune system.

The British government attacked the initial agreement for the vaccine, later increasing its order to 100 million doses.

On Tuesday, the academics involved in the trial wrote that it was one of six Covid 19 vaccines in the world that are currently in the third phase - the final step before a vaccine is approved.

He wrote that the vaccine is being tested in the UK by health workers as well as public volunteers over the age of 70.

As of Tuesday, 17,000 people in Britain, Brazil and South Africa had already been vaccinated’ against polio.

Robert Booy, a professor of vaccinology at the University of Sydney, told the Guardian that preventing a trial based on a participant's reaction "is likely to be extremely careful to avoid." In contrast, there is no problem with this vaccine.

Booy, who has previously worked on vaccine development at Oxford, said he understood why the details of the adverse reaction were not released’ as specific side effects and "stops" could occur if the problem persisted. Too much detail can make the study biased. “To be irregular

He said stopping the trial of the vaccine was not uncommon.

 "When you're vaccinating more than 10,000 people, coincidentally, there will be weird and wonderful things going on with the participants that were going to happen anyway. The hearing needs to be, stopped.

Booy believes the trial could resume within a month if the possible co-investigation provides "reassuring results", but said that if such negative reactions occur. If more cases are reported’ more questions will be raised’ about vaccine safety.

"It could just be a high fever, and it shows that he has appendicitis," he said.

"My condition is that they find something in the partner that doesn't work [with the vaccine]. It will take them one to two weeks to figure it out, and then maybe they'll have a trial in a month," Booy said. Will resume hearing.


The death toll from a mine collapse in NWFP has risen to 22

Post a Comment